Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 85/100

Failure Rate

25.0%

1 terminated/withdrawn out of 4 trials

Success Rate

0.0%

-86.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A
3(75.0%)
Early Phase 1
1(25.0%)
4Total
N/A(3)
Early Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT05776355Not ApplicableUnknown

NKG2D CAR-NK & Ovarian Cancer

Role: lead

NCT05734898Not ApplicableUnknown

NKG2D CAR-NK & r/rAML

Role: collaborator

NCT05247957Not ApplicableTerminated

NKG2D CAR-NK Cell Therapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia

Role: lead

NCT05248048Early Phase 1Unknown

NKG2D CAR-T Cells to Treat Patients With Previously Treated Liver Metastatic Colorectal Cancer

Role: collaborator

All 4 trials loaded